Adult Genomics —
Training activity: 3

Details

Analyse and interpret the results from targeted testing for patients referred for infertility, to include:

• Cystic fibrosis
• FMR1 analysis in relation to premature ovarian failure (POF)

Type

Developmental training activity (DTA)

Evidence requirements

Evidence the activity has been undertaken by the trainee​.

Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.

An action plan to implement learning and/or to address skills or knowledge gaps identified.

Reflective practice guidance

The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.

Before action

• What do you already know about cystic fibrosis mutations, FMR1 gene expansions, and their association with infertility and POF?
• What specific insights do you hope to gain from analysing these targeted testing results (e.g., understanding different types of CF mutations or FMR1 repeat sizes)?
• What actions will you take in preparation for interpreting these results? Will you familiarise yourself with the relevant genetic information, inheritance patterns, and potential implications?
• What possible challenges might you anticipate when interpreting these targeted results and how might you handle them?

In action

• Describe the specific steps you are currently taking to analyse the results of the cystic fibrosis testing and/or FMR1 analysis. What testing methods are you using?
• How are you interpreting different results?
• What aspects of interpreting these targeted results feel intuitive or based on prior knowledge, and what requires more conscious effort or reference to guidelines and resources?
• If applicable, how are you correlating the FMR1 repeat size with the clinical presentation of premature ovarian failure?
• How effective are your current strategies in identifying relevant genetic findings related to infertility in these targeted tests?
• What challenges are you encountering in this moment, such as interpreting results with borderline repeat numbers in FMR1, , or dealing with technical issues in the data?
• What can you learn from the data as it unfolds? Are there any unexpected findings or patterns emerging that you need to investigate further?
• How does this activity connect to your existing knowledge of the genetic mechanisms underlying cystic fibrosis and fragile X-associated premature ovarian insufficiency?
• Are there alternative analysis or interpretation approaches you could consider if your initial assessment is unclear or if you encounter unexpected results (e.g., reviewing raw data, consulting with a senior colleague)?
• What immediate support or guidance might you need if you are uncertain about the clinical significance of a particular finding or how to interpret a complex result?
• Are you ensuring that your interpretation remains within the scope of established laboratory protocols and your level of training and ability?

 

On action

• What were the results of the cystic fibrosis testing and/or FMR1 analysis that you interpreted?
  • Were any pathogenic variants or repeat expansions identified?
  • In cases involving FMR1 analysis, what was the correlation between the repeat size and the clinical information regarding premature ovarian failure (if available)?
  • Were there any technical or interpretative challenges encountered during the analysis of these targeted tests?
• Did you enhance your understanding of the interpretation of results for cystic fibrosis testing and FMR1 analysis in the context of infertility?
  • Did you gain more insight into the clinical significance of different types of findings (e.g., heterozygous vs. homozygous CFTR , different FMR1 repeat ranges)?
• What areas for continued learning have you identified regarding the interpretation of targeted testing for infertility?
  • How will you apply the knowledge gained from this activity to future analyses of cystic fibrosis and FMR1 results in similar clinical scenarios?
  • What further investigation or learning will you undertake to improve your understanding of these specific genetic tests and their implications for infertility?
  • What resources or support would be beneficial for your ongoing development in this area of adult genomics?

Beyond action

• Reflect on your initial interpretation of cystic fibrosis and FMR1 analysis results. Have you encountered more cases involving these tests since then?
• Consider any new guidelines or information that have emerged regarding the interpretation of these tests. How do these updates influence your understanding of the cases you previously analysed?
• Have you compared your approach to interpreting these results with colleagues? Has this provided any new insights?
• How has your ability to interpret targeted testing results for infertility (specifically CF and FMR1) improved since this training activity?
• Are you now more aware of the nuances associated with different types of findings (e.g., carrier status, pre-mutation alleles)? Can you trace this increased awareness back to this specific training activity?
• Have you had to explain these types of results to other healthcare professionals? How did your experience with this training activity influence your ability to do so effectively?
• What broader skills in interpreting molecular genetic test results did you hone through this activity that will be applicable to other targeted assays in the future?
• How has this experience contributed to your understanding of the importance of correlating genetic findings with clinical information in the context of infertility?

Relevant learning outcomes

#	Outcome
# 2	Outcome Perform molecular analysis for patients referred with adult-onset disorders.
# 4	Outcome Interpret genomic variants, including copy number and structural changes and investigate the clinical significance of variants using bioinformatic tools using best practice guidelines.